![]() Clickotine users reported encouraging quit rates while reporting few adverse events. Few adverse events, mostly consistent with nicotine withdrawal symptoms, were reported and overall no safety signal was detected.Ĭonclusions: In this initial single-arm trial, Clickotine users appeared to demonstrate encouraging indicators of engagement in terms of the number of app opens, number of program interactions, and continued engagement over time. Completer analysis focused on 365 (87.7%) of the 416 enrolled participants who completed the 8-week questionnaire revealed that 51.5% (188/365) of completers reported 7-day abstinence and 29.9% (109/365) reported 30-day abstinence. Among the ITT sample, 45.2% (188/416) reported 7-day abstinence and 26.2% (109/416) reported 30-day abstinence from smoking after 8 weeks. ![]() On average, participants opened the Clickotine app 100.6 times during the 8-week study (median 69), logged 214.4 interactions with the Clickotine program (median 178), and remained engaged with Clickotine for 5.3 weeks (median 5). ![]() Results: A total of 416 participants downloaded the app and constituted the intention-to-treat (ITT) sample. Data were collected in Amazon S3 with no manual data entry, and access to all data was maximally restrictive, logged, and auditable. Participants completed study assessments via the online portal at baseline and after 8 weeks. Respondents were prescreened for eligibility by telephone and, if appropriate, directed to a Web portal to provide informed consent, confirm eligibility, and download the Clickotine app. Methods: We recruited US residents between 18 and 65 years of age who owned an iPhone and smoked 5 or more cigarettes daily for the study via online advertising. Outcomes measured were indicators of engagement with the smartphone app (number of app opens, number of interactions with the Clickotine program, and weeks active with Clickotine), cessation outcomes of 7- and 30-day self-reported abstinence from smoking, and negative health events. Objective: Our objective was to assess the engagement, efficacy, and safety of Clickotine in an initial, single-arm study. Clickotine is a novel smartphone app for smoking cessation, designed to deliver the essential features of the USCPG and engineered to engage smokers by personalizing intervention components. Technology can help overcome these obstacles many smartphone apps have been developed to aid smoking cessation, but few that conform to the US clinical practice guideline (USCPG) have been rigorously tested and reported in the literature. Obstacles to smoking cessation include limited access and adherence to effective cessation interventions. Online Journal of Public Health InformaticsĮmail: Tobacco smoking is the leading cause of preventable death in the United States, and the annual economic burden attributable to smoking exceeds US $300 billion.Asian/Pacific Island Nursing Journal 13 articles.JMIR Bioinformatics and Biotechnology 38 articles.JMIR Biomedical Engineering 74 articles.Journal of Participatory Medicine 82 articles.JMIR Perioperative Medicine 100 articles.JMIR Rehabilitation and Assistive Technologies 225 articles.JMIR Pediatrics and Parenting 304 articles.Interactive Journal of Medical Research 340 articles.JMIR Public Health and Surveillance 1248 articles.Journal of Medical Internet Research 7993 articles.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |